The Immunology of CD1- and MR1-Restricted T Cells

Annual Review of Immunology

Volumn 34, Issue , 2016, Pages 479-510

  Mori, Lucia ^a,b   Lepore, Marco ^a   De Libero, Gennaro ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

Antigen presentation; Autoimmune diseases; Infectious diseases; Innate like T cells; Lipid antigens; Metabolite antigens; Mucosal associated invariant T cells; Natural killer T cells; T cell receptor; Tumor immunity

Indexed keywords

CD1 ANTIGEN; GLYCOSPHINGOLIPID; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHOLIPID; T LYMPHOCYTE RECEPTOR; ANTIGEN; HLA ANTIGEN CLASS 1; LYMPHOCYTE ANTIGEN RECEPTOR; MINOR HISTOCOMPATIBILITY ANTIGEN; MR1 PROTEIN, HUMAN; PROTEIN BINDING;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CELL MATURATION; CELL SELECTION; CHOLERA; DENDRITIC CELL; EFFECTOR CELL; ESCHERICHIA COLI; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER T CELL; NONHUMAN; PARATUBERCULOSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; AUTOIMMUNE DISEASE; GENETICS; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER CELL; NEOPLASM; PHYSIOLOGY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, CD1; AUTOIMMUNE DISEASES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFECTION; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MINOR HISTOCOMPATIBILITY ANTIGENS; NATURAL KILLER T-CELLS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL;

EID: 84969752983     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032414-112008     Document Type: Review

References (221)

1. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, et al. 1999. An invariant T cell receptor α chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted α/βT cell subpopulation in mammals. J. Exp. Med. 189:1907-21
2. Kawachi I,Maldonado J, Strader C, Gilfillan S. 2006. MR1-restrictedVα19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. J. Immunol. 176:1618-27
3. Brennan PJ, Brigl M, Brenner MB. 2013. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13:101-17
4. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, et al. 2013. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLOS Pathog. 9:e1003681
5. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, et al. 2011. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J. Exp. Med. 208:1163-77
6. Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, et al. 2014. CD161++CD8+ Tcells, including theMAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur. J. Immunol. 44:195-203
7. Le Bourhis L,Mburu YK, Lantz O. 2013. MAIT cells, surveyors of a new class of antigen: development and functions. Curr. Opin. Immunol. 25:174-80
8. Bendelac A. 1995. Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J. Exp. Med. 182:2091-96
9. Seach N, Guerri L, Le Bourhis L, Mburu Y, Cui Y, et al. 2013. Double-positive thymocytes select mucosal-associated invariant T cells. J. Immunol. 191:6002-9
10. Constantinides MG, Bendelac A. 2013. Transcriptional regulation of the NKT cell lineage. Curr. Opin. Immunol. 25:161-67
11. Salio M, Silk JD, Jones EY, Cerundolo V. 2014. Biology of CD1-and MR1-restricted T cells. Annu. Rev. Immunol. 32:323-66
12. Chandra S, Kronenberg M. 2015. Activation and function of iNKT and MAIT cells. Adv. Immunol. 127:145-201
13. Kumar V, Delovitch TL. 2014. Different subsets of natural killer T cells may vary in their roles in health and disease. Immunology 142:321-36
14. DusseauxM,Martin E, SerriariN, Peguillet I, Premel V, et al. 2011. HumanMAIT cells are xenobioticresistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117:1250-59
15. Lepore M, Kalinichenko A, Colone A, Paleja B, Singhal A, et al. 2014. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβrepertoire. Nat. Commun. 5:3866
16. de Lalla C, Lepore M, Piccolo FM, Rinaldi A, Scelfo A, et al. 2011. High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells. Eur. J. Immunol. 41:602-10
17. LeporeM, Lalla C, Gundimeda SR, GsellingerH, Consonni M, et al. 2014. A novel self-lipid antigen targets human T cells against CD1c+ leukemias. J. Exp. Med. 211:1363-77
18. de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. 2010. CD1a-autoreactive T cells are a normal component of the human αβT cell repertoire. Nat. Immunol. 11:1102-9
19. Dascher CC, Brenner MB. 2003. Evolutionary constraints on CD1 structure: insights from comparative genomic analysis. Trends Immunol. 24:412-18
20. Tourne S, Maitre B, Collmann A, Layre E, Mariotti S, et al. 2008. Cutting edge: a naturally occurring mutation in CD1e impairs lipid antigen presentation. J. Immunol. 180:3642-46
21. Geng Y, Laslo P, Barton K, Wang CR. 2005. Transcriptional regulation of CD1D1 by Ets family transcription factors. J. Immunol. 175:1022-29
22. Sikder H, Zhao Y, Balato A, Chapoval A, Fishelevich R, et al. 2009. A central role for transcription factor C/EBP-βin regulating CD1d gene expression in human keratinocytes. J. Immunol. 183:1657-66
23. Chen QY, Zhang T, Pincus SH,Wu S, Ricks D, et al. 2010. Human CD1D gene expression is regulated by LEF-1 through distal promoter regulatory elements. J. Immunol. 184:5047-54
24. Chen Q, Ross AC. 2007. Retinoic acid regulates CD1d gene expression at the transcriptional level in human and rodent monocytic cells. Exp. Biol. Med. 232:488-94
25. Szatmari I, Pap A, Ruhl R, Ma JX, Illarionov PA, et al. 2006. PPARγ controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J. Exp. Med. 203:2351-62
26. Yang PM, Lin PJ, Chen CC. 2012. CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1. Epigenetics 7:390-99
27. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. 2015. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33:169-200
28. De Libero G, Mori L. 2012. Novel insights into lipid antigen presentation. Trends Immunol. 33:103-11
29. Birkinshaw RW, Pellicci DG, ChengTY, Keller AN, Sandoval-Romero M, et al. 2015.αβTcell antigen receptor recognition of CD1a presenting self lipid ligands. Nat. Immunol. 16:258-66
30. Riegert P, Wanner V, Bahram S. 1998. Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. J. Immunol. 161:4066-77
31. Lopez-Sagaseta J, Dulberger CL, Crooks JE, Parks CD, Luoma AM, et al. 2013. The molecular basis for mucosal-associated invariant T cell recognition of MR1 proteins. PNAS 110:E1771-78
32. Patel O, Kjer-Nielsen L, Le Nours J, Eckle SB, Birkinshaw R, et al. 2013. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat. Commun. 4:2142
33. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, et al. 2014. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 509:361-65
34. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J,Meehan B, et al. 2012. MR1 presentsmicrobial vitamin B metabolites to MAIT cells. Nature 491:717-23
35. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G. 1999. Self glycolipids as T-cell autoantigens. Eur. J. Immunol. 29:1667-75
36. Shamshiev A, Donda A, Prigozy TI, Mori L, Chigorno V, et al. 2000. The αβT cell response to selfglycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity 13:255-64
37. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198:173-81
38. Zhou D, Mattner J, Cantu C, Schrantz N, Yin N, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306:1786-89
39. Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G. 2002. Presentation of the same glycolipid by different CD1 molecules. J. Exp. Med. 195:1013-21
40. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199:947-57
41. BlomqvistM, Rhost S, Teneberg S, Lofbom L, Osterbye T, et al. 2009. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur. J. Immunol. 39:1726-35
42. Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, et al. 2012. The majority of CD1d-sulfatidespecific T cells in human blood use a semiinvariant Vδ1 TCR. Eur. J. Immunol. 42:2505-10
43. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, et al. 2013. CD1d-lipid antigen recognition by the γδ TCR. Nat. Immunol. 14:1137-45
44. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, et al. 2000. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211-21
45. Tatituri RV,Watts GF, Bhowruth V, Barton N, Rothchild A, et al. 2013. Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. PNAS 110:1827-32
46. Van Rhijn I, van Berlo T, Hilmenyuk T, Cheng T-Y, Wolf BJ, et al. 2015. Human autoreactive T cells recognize CD1b and phospholipids. PNAS 113:380-85
47. LandsWE. 1960. Metabolism of glycerolipids. II. The enzymatic acylation of lysolecithin. J. Biol. Chem. 235:2233-37
48. CoxD, Fox L, Tian R, Bardet W, SkaleyM, et al. 2009. Determination of cellular lipids bound to human CD1d molecules. PLOS ONE 4:e5325
49. Yuan W, Kang SJ, Evans JE, Cresswell P. 2009. Natural lipid ligands associated with human CD1d targeted to different subcellular compartments. J. Immunol. 182:4784-91
50. Fox LM, Cox DG, Lockridge JL, Wang X, Chen X, et al. 2009. Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLOS Biol. 7:e1000228
51. Lopez-Sagaseta J, Sibener LV, Kung JE, Gumperz J, Adams EJ. 2012. Lysophospholipid presentation by CD1d and recognition by a human natural killer T-cell receptor. EMBO J. 31:2047-59
52. de Jong A, ChengTY, Huang S,Gras S,BirkinshawRW,et al. 2014. CD1a-autoreactiveTcells recognize natural skin oils that function as headless antigens. Nat. Immunol. 15:177-85
53. Facciotti F, Ramanjaneyulu GS,LeporeM, Sansano S, CavallariM, et al. 2012. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat. Immunol. 13:474-80
54. Kain L, Webb B, Anderson BL, Deng S, Holt M, et al. 2014. The identification of the endogenous ligands of natural killer T cells reveals the presence ofmammalianα-linked glycosylceramides. Immunity 41:543-54
55. De Libero G, Moran AP, Gober HJ, Rossy E, Shamshiev A, et al. 2005. Bacterial infections promote T cell recognition of self-glycolipids. Immunity 22:763-72
56. Salio M, Speak AO, Shepherd D, Polzella P, Illarionov PA, et al. 2007. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. PNAS 104:20490-95
57. Paget C,Mallevaey T, Speak AO, TorresD, Fontaine J, et al. 2007. Activation of invariantNKT cells by Toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 27:597-609
58. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. 1994. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 372:691-94
59. Moody DB, Reinhold BB, GuyMR, Beckman EM, Frederique DE, et al. 1997. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Science 278:283-86
60. Layre E, Collmann A, Bastian M, Mariotti S, Czaplicki J, et al. 2009. Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells. Chem. Biol. 16:82-92
61. Gilleron M, Stenger S, Mazorra Z, Wittke F, Mariotti S, et al. 2004. Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J. Exp. Med. 199:649-59
62. Moody DB, Ulrichs T, Muhlecker W, Young DC, Gurcha SS, et al. 2000. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404:884-88
63. Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Mazzaccaro RJ, et al. 1995. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 269:227-30
64. Zajonc DM, Ainge GD, Painter GF, Severn WB, Wilson IA. 2006. Structural characterization of mycobacterial phosphatidylinositol mannoside binding to mouse CD1d. J. Immunol. 177:4577-83
65. de la Salle H, Mariotti S, Angenieux C, GilleronM, Garcia-Alles LF, et al. 2005. Assistance of microbial glycolipid antigen processing by CD1e. Science 310:1321-24
66. Ernst WA, Maher J, Cho S, Niazi KR, Chatterjee D, et al. 1998. Molecular interaction of CD1b with lipoglycan antigens. Immunity 8:331-40
67. Moody DB, Young DC, Cheng TY, Rosat JP, Roura-Mir C, et al. 2004. T cell activation by lipopeptide antigens. Science 303:527-31
68. Zajonc DM, Crispin MD, Bowden TA, Young DC, Cheng TY, et al. 2005. Molecular mechanism of lipopeptide presentation by CD1a. Immunity 22:209-19
69. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. PNAS 95:5690-93
70. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, et al. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520-25
71. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525-29
72. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. 2005. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35:1692-701
73. Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, et al. 2013. Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLOS Biol. 11:e1001610
74. Albacker LA, Chaudhary V, Chang YJ, Kim HY, Chuang YT, et al. 2013. Invariant natural killer T cells recognize a fungal glycosphingolipid that can induce airway hyperreactivity. Nat. Med. 19:1297-304
75. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, et al. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7:978-86
76. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, et al. 2011. Invariant natural killer T cells recognize glycolipids from pathogenic gram-positive bacteria. Nat. Immunol. 12:966-74
77. Chang YJ, Kim HY, Albacker LA, Lee HH, Baumgarth N, et al. 2011. Influenza infection in suckling mice expands anNKT cell subset that protects against airway hyperreactivity. J. Clin. Investig. 121:57-69
78. ItoY,Vela JL, Matsumura F,Hoshino H, TyznikA, et al. 2013. Helicobacter pylori cholesterylα-glucosides contribute to its pathogenicity and immune response by natural killer T cells. PLOS ONE 8:e78191
79. Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, et al. 2015. In vitro and in vivo analysis of the gram-negative bacteria-derived riboflavin precursor derivatives activating mouse MAIT cells. J. Immunol. 194:4641-49
80. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, et al. 2010. Antimicrobial activity of mucosalassociated invariant T cells. Nat. Immunol. 11:701-8
81. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, et al. 2010. Human mucosal associated invariant T cells detect bacterially infected cells. PLOS Biol. 8:e1000407
82. Freigang S, Kain L, Teyton L. 2013. Transport and uptake of immunogenic lipids. Mol. Immunol. 55:179-81
83. Freigang S, Zadorozhny V, McKinney MK, Krebs P, Herro R, et al. 2010. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice. J. Clin. Investig. 120:1873-84
84. Freigang S, Landais E, Zadorozhny V, Kain L, Yoshida K, et al. 2012. Scavenger receptors target glycolipids for natural killer T cell activation. J. Clin. Investig. 122:3943-54
85. Zhou D, Cantu C, Sagiv Y, Schrantz N, Kulkarni AB, et al. 2004. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303:523-27
86. Facciotti F, Cavallari M, Angenieux C, Garcia-Alles LF, Signorino-Gelo F, et al. 2011. Fine tuning by human CD1e of lipid-specific immune responses. PNAS 108:14228-33
87. Salio M, Puleston DJ, Mathan TS, Shepherd D, Stranks AJ, et al. 2014. Essential role for autophagy during invariant NKT cell development. PNAS 111:E5678-87
88. Pei B, Zhao M, Miller BC, Vela JL, Bruinsma MW, et al. 2015. Invariant NKT cells require autophagy to coordinate proliferation and survival signals during differentiation. J. Immunol. 194:5872-84
89. Garcia-AllesLF, Versluis K, MaveyraudL, VallinaAT, Sansano S, et al. 2006. Endogenous phosphatidylcholine and a long spacer ligand stabilize the lipid-binding groove of CD1b. EMBO J. 25:3684-92
90. Garcia-Alles LF, Collmann A, Versluis C, Lindner B, Guiard J, et al. 2011. Structural reorganization of the antigen-binding groove of human CD1b for presentation of mycobacterial sulfoglycolipids. PNAS 108:17755-60
91. Huang S, Cheng TY, Young DC, Layre E, Madigan CA, et al. 2011. Discovery of deoxyceramides and diacylglycerols as CD1b scaffold lipids among diverse groove-blocking lipids of the human CD1 system. PNAS 108:19335-40
92. Wun KS, Cameron G, Patel O, Pang SS, Pellicci DG, et al. 2011. A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killerTcells. Immunity 34:327-39
93. Gadola SD, Zaccai NR, Harlos K, Shepherd D, Castro-Palomino JC, et al. 2002. Structure of human CD1b with bound ligands at 2.3A , a maze for alkyl chains. Nat. Immunol. 3:721-26
94. Scharf L, Li NS,Hawk AJ, Garzon D, ZhangT, et al. 2010. The 2.5A structure ofCD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity 33:853-62
95. Relloso M, Cheng TY, Im JS, Parisini E, Roura-Mir C, et al. 2008. pH-dependent interdomain tethers of CD1b regulate its antigen capture. Immunity 28:774-86
96. Miley MJ, Truscott SM, Yu YY, Gilfillan S, Fremont DH, et al. 2003. Biochemical features of the MHC-related protein 1 consistent with an immunological function. J. Immunol. 170:6090-98
97. Huang S, Gilfillan S, Kim S, Thompson B, Wang X, et al. 2008. MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells. J. Exp. Med. 205:1201-11
98. Porcelli S, Yockey CE, Brenner MB, Balk SP. 1993. Analysis ofTcell antigen receptor (TCR) expression by human peripheral blood CD4-8-α/βT cells demonstrates preferential use of several Vβgenes and an invariant TCR αchain. J. Exp. Med. 178:1-16
99. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. 1994. An invariant Vα24-JαQ/Vβ11 T cell receptor is expressed in all individuals by clonally expanded CD4-8-T cells. J. Exp. Med. 180:1171-76
100. Gadola SD, Dulphy N, Salio M, Cerundolo V. 2002. Vα24-JαQ-independent, CD1d-restricted recognition ofα-galactosylceramide by humanCD4+ andCD8αβ+ Tlymphocytes. J. Immunol. 168:5514-20
101. Uldrich AP, Patel O, Cameron G, Pellicci DG, Day EB, et al. 2011. A semi-invariant Vα10+ T cell antigen receptor defines a population of natural killer Tcells with distinct glycolipid antigen-recognition properties. Nat. Immunol. 12:616-23
102. Van Rhijn I, Kasmar A, Jong A, Gras S, Bhati M, et al. 2013. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nat. Immunol. 14:706-13
103. Van Rhijn I, Gherardin NA, Kasmar A, de Jager W, Pellicci DG, et al. 2014. TCR bias and affinity define two compartments of the CD1b-glycolipid-specific T cell repertoire. J. Immunol. 192:4054-60
104. Gold MC, McLaren JE, Reistetter JA, Smyk-Pearson S, Ladell K, et al. 2014. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J. Exp. Med. 211:1601-10
105. Brigl M, van Elzen P, Chen X, Meyers JH, Wu D, et al. 2006. Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors. J. Immunol. 176:3625-34
106. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, et al. 2013. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J. Exp. Med. 210:2305-20
107. Borg NA,Wun KS,Kjer-NielsenL,WilceMC,PellicciDG,et al. 2007. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448:44-49
108. Girardi E, Maricic I, Wang J, Mac TT, Iyer P, et al. 2012. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat. Immunol. 13:851-56
109. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, et al. 2012. Recognition of CD1dsulfatide mediated by a type II natural killer T cell antigen receptor. Nat. Immunol. 13:857-63
110. Luoma AM, Castro CD, Mayassi T, Bembinster LA, Bai L, et al. 2013. Crystal structure of Vδ1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human γδ T cells. Immunity 39:1032-42
111. Pellicci DG, Uldrich AP, Le Nours J, Ross F, Chabrol E, et al. 2014. The molecular bases of δ/αβ T cell-mediated antigen recognition. J. Exp. Med. 211:2599-615
112. Roy S, Ly D, Li NS, Altman JD, Piccirilli JA, et al. 2014. Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by αβT cells. PNAS 111:E4648-57
113. Dascher CC, Hiromatsu K, Xiong X, Morehouse C, Watts G, et al. 2003. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int. Immunol. 15:915-25
114. Felio K, Nguyen H, Dascher CC, Choi HJ, Li S, et al. 2009. CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. J. Exp. Med. 206:2497-509
115. Kumar H, Belperron A, Barthold SW, Bockenstedt LK. 2000. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi. J. Immunol. 165:4797-801
116. Nieuwenhuis EE, Matsumoto T, Exley M, Schleipman RA, Glickman J, et al. 2002. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat. Med. 8:588-93
117. Joyee AG, Qiu H, Wang S, Fan Y, Bilenki L, Yang X. 2007. Distinct NKT cell subsets are induced by different Chlamydia species leading to differential adaptive immunity and host resistance to the infections. J. Immunol. 178:1048-58
118. Kawakami K, Kinjo Y, Yara S, Koguchi Y, Uezu K, et al. 2001. Activation of Vα14+ natural killer T cells by α-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69:213-20
119. Cohen NR, Tatituri RV, Rivera A, Watts GF, Kim EY, et al. 2011. Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 10:437-50
120. Sousa AO, Mazzaccaro RJ, Russell RG, Lee FK, Turner OC, et al. 2000. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. PNAS 97:4204-8
121. Chackerian A, Alt J, Perera V, Behar SM. 2002. Activation ofNKTcells protects mice from tuberculosis. Infect. Immun. 70:6302-9
122. Sada-Ovalle I, Chiba A,Gonzales A, Brenner MB, Behar SM. 2008. Innate invariantNKTcells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-γ, and kill intracellular bacteria. PLOS Pathog. 4:e1000239
123. Kawakami K, Yamamoto N, Kinjo Y, Miyagi K, Nakasone C, et al. 2003. Critical role of Vα14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur. J. Immunol. 33:3322-30
124. Gonzalez-Aseguinolaza G, Oliveira C, Tomaska M, Hong S, Bruna-Romero O, et al. 2000. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. PNAS 97:8461-66
125. Karmakar S, Bhaumik SK, Paul J, De T. 2012. TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLOS Pathog. 8:e1002646
126. Grubor-Bauk B, Arthur JL, MayrhoferG. 2008. Importance ofNKTcells in resistance to herpes simplex virus, fate of virus-infected neurons, and level of latency in mice. J. Virol. 82:11073-83
127. Ho LP, Denney L, Luhn K, Teoh D, Clelland C, McMichael AJ. 2008. Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur. J. Immunol. 38:1913-22
128. Tyznik AJ, Verma S,Wang Q, KronenbergM, Benedict CA. 2014. Distinct requirements for activation of NKT and NK cells during viral infection. J. Immunol. 192:3676-85
129. De Santo C, Salio M, Masri SH, Lee LY, Dong T, et al. 2008. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Investig. 118:4036-48
130. Paget C, Ivanov S, Fontaine J, Blanc F, PichavantM, et al. 2011. Potential role of invariantNKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. J. Immunol. 186:5590-602
131. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. 2000. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192:921-30
132. Zeissig S,Murata K, Sweet L, Publicover J, Hu Z, et al. 2012. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat. Med. 18:1060-68
133. Bilenki L,Wang S, Yang J, Fan Y, Joyee AG, Yang X. 2005. NK T cell activation promotes Chlamydia trachomatis infection in vivo. J. Immunol. 175:3197-206
134. Hill TM, Gilchuk P, Cicek BB, Osina MA, Boyd KL, et al. 2015. Border patrol gone awry: Lung NKT cell activation by Francisella tularensis exacerbates tularemia-like disease. PLOS Pathog. 11:e1004975
135. Van Rhijn I, Nguyen TK, Michel A, Cooper D, Govaerts M, et al. 2009. Low cross-reactivity of T-cell responses against lipids from Mycobacterium bovis and M. avium paratuberculosis during natural infection. Eur. J. Immunol. 39:3031-41
136. Kee SJ, Kwon YS, Park YW, Cho YN, Lee SJ, et al. 2012. Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection. Infect. Immun. 80:2100-8
137. Sutherland JS, Jeffries DJ, Donkor S, Walther B, Hill PC, et al. 2009. High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting. Tuberculosis 89:398-404
138. Montamat-Sicotte DJ, Millington KA,Willcox CR, Hingley-Wilson S, Hackforth S, et al. 2011. A mycolic acid-specific CD1-restricted Tcell population contributes to acute andmemory immune responses in human tuberculosis infection. J. Clin. Investig. 121:2493-503
139. Ulrichs T, Moody DB, Grant E, Kaufmann SH, Porcelli SA. 2003. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect. Immun. 71:3076-87
140. Yuan W, Dasgupta A, Cresswell P. 2006. Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling. Nat. Immunol. 7:835-42
141. Yanagisawa K, Yue S, van Vliet HJ, Wang R, Alatrakchi N, et al. 2013. Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C. J. Viral Hepat. 20:556-65
142. Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, et al. 2001. Circulating Vα24+ Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100:144-48
143. Moll M, Snyder-Cappione J, Spotts G, Hecht FM, Sandberg JK, Nixon DF. 2006. Expansion of CD1drestrictedNKTcells in patients with primaryHIV-1 infection treated with interleukin-2. Blood 107:3081-83
144. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. 2008. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111:5637-45
145. Georgel P, Radosavljevic M, Macquin C, Bahram S. 2011. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol. Immunol. 48:769-75
146. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. 2012. Polyclonal mucosaassociated invariantTcells have unique innate functions in bacterial infection. Infect. Immun. 80:3256-67
147. Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, et al. 2013. Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12:546-58
148. Meierovics A, Yankelevich WJ, Cowley SC. 2013. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. PNAS 110:E3119-28
149. Leung DT, Bhuiyan TR, Nishat NS, Hoq MR, Aktar A, et al. 2014. Circulating mucosal associated invariant T cells are activated in Vibrio cholerae O1 infection and associated with lipopolysaccharide antibody responses. PLOS Negl. Trop. Dis. 8:e3076
150. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, et al. 2014. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med. 40:192-201
151. Cosgrove C, Ussher JE, Rauch A, Gartner K, Kurioka A, et al. 2013. Early and nonreversible decrease of CD161++/MAIT cells in HIV infection. Blood 121:951-61
152. Leeansyah E, Ganesh A, Quigley MF, Sonnerborg A, Andersson J, et al. 2013. Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood 121:1124-35
153. Yanagihara Y, Shiozawa K, Takai M, Kyogoku M, Shiozawa S. 1999. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 118:131-36
154. Linsen L, ThewissenM, Baeten K, Somers V, Geusens P, et al. 2005. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res. Ther. 7:R493-502
155. Parietti V, ChifflotH, Sibilia J, Muller S,Monneaux F. 2010. Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Clin. Immunol. 134:331-39
156. Jacques P, Venken K, Van Beneden K, Hammad H, Seeuws S, et al. 2010. Invariant natural killer T cells are natural regulators of murine spondylarthritis. Arthritis Rheum. 62:988-99
157. Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S. 2011. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J. Clin. Investig. 121:249-64
158. Miellot-Gafsou A, Biton J, Bourgeois E, Herbelin A, Boissier MC, Bessis N. 2010. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Immunology 130:296-306
159. Kim HY, Kim HJ, Min HS, Kim S, Park WS, et al. 2005. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor β1 production. J. Exp. Med. 201:41-47
160. ArakiM, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T. 2003. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int. Immunol. 15:279-88
161. Oh SJ, Chung DH. 2011. InvariantNKT cells producing IL-4 or IL-10, but not IFN-γ, inhibit the Th1 response in experimental autoimmune encephalomyelitis, whereas none of these cells inhibits the Th17 response. J. Immunol. 186:6815-21
162. Mars LT, Gautron AS, Novak J, Beaudoin L, Diana J, et al. 2008. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J. Immunol. 181:2321-29
163. Kojo S, Adachi Y, Keino H, TaniguchiM, Sumida T. 2001. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 44:1127-38
164. Sieling PA, Porcelli SA, Duong BT, Spada F, Bloom BR, et al. 2000. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J. Immunol. 165:5338-44
165. Forestier C, Molano A, Im JS, Dutronc Y, Diamond B, et al. 2005. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New ZealandWhite)F1 mice. J. Immunol. 175:763-70
166. TakahashiT, Strober S. 2008. Natural killerTcells and innate immuneBcells from lupus-proneNZB/W mice interact to generate IgM and IgG autoantibodies. Eur. J. Immunol. 38:156-65
167. Yang JQ, Chun T, Liu H, Hong S, Bui H, et al. 2004. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur. J. Immunol. 34:1723-32
168. Magalhaes I, Kiaf B, Lehuen A. 2015. iNKT and MAIT cell alterations in diabetes. Front. Immunol. 6:341
169. Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, et al. 2001. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. PNAS 98:6777-82
170. Fletcher MT, Baxter AG. 2009. Clinical application ofNKTcell biology in type I (autoimmune) diabetes mellitus. Immunol. Cell Biol. 87:315-23
171. Ly D, Mi QS, Hussain S, Delovitch TL. 2006. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J. Immunol. 177:3695-704
172. Forestier C, Takaki T,Molano A, Im JS, Baine I, et al. 2007. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J. Immunol. 178:1415-25
173. Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A. 2013. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: Are we close to reality? Clin. Exp. Immunol. 171:8-19
174. ExleyMA, Hand L, O'Shea D, Lynch L. 2014. Interplay between the immune system and adipose tissue in obesity. J. Endocrinol. 223:R41-48
175. Lynch L, Michelet X, Zhang S, Brennan PJ, Moseman A, et al. 2015. Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of Treg cells and macrophages in adipose tissue. Nat. Immunol. 16:85-95
176. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. 1999. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch. Dermatol. 135:546-52
177. Gilhar A, Ullmann Y, Kerner H, Assy B, Shalaginov R, et al. 2002. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J. Investig. Dermatol. 119:384-91
178. Tupin E, Nicoletti A, Elhage R, RudlingM, Ljunggren HG, et al. 2004. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199:417-22
179. Kyriakakis E, CavallariM, Andert J, PhilippovaM, Koella C, et al. 2010. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur. J. Immunol. 40:3268-79
180. Melian A, Geng YJ, Sukhova GK, Libby P, Porcelli SA. 1999. CD1 expression in human atherosclerosis: a potential mechanism for T cell activation by foam cells. Am. J. Pathol. 155:775-86
181. Zeissig S, Blumberg RS. 2013. Commensal microbiota and NKT cells in the control of inflammatory diseases at mucosal surfaces. Curr. Opin. Immunol. 25:690-96
182. Akbari O, Stock P,Meyer E, Kronenberg M, Sidobre S, et al. 2003. Essential role ofNKTcells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9:582-88
183. Meyer EH, Goya S, Akbari O, Berry GJ, Savage PB, et al. 2006. Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. PNAS 103:2782-87
184. Matangkasombut P, Pichavant M, Yasumi T, Hendricks C, Savage PB, et al. 2008. Direct activation of natural killer T cells induces airway hyperreactivity in nonhuman primates. J. Allergy Clin. Immunol. 121:1287-89
185. Nambiar J, Clarke AW, ShimD,Mabon D, Tian C, et al. 2015. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model. mAbs 7:638-50
186. Berzins SP, Ritchie DS. 2014. Natural killer T cells: drivers or passengers in preventing human disease? Nat. Rev. Immunol. 14:640-46
187. Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF. 2013. Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol. Genet. Metab. 108:241-48
188. Nair S, Boddupalli CS, Verma R, Liu J, Yang R, et al. 2015. Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood 125:1256-71
189. Croxford JL, Miyake S, Huang YY, Shimamura M, Yamamura T. 2006. Invariant Vα19i T cells regulate autoimmune inflammation. Nat. Immunol. 7:987-94
190. Miyazaki Y, Miyake S, Chiba A, Lantz O, Yamamura T. 2011. Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis. Int. Immunol. 23:529-35
191. Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, et al. 2013. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136:2888-903
192. Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, et al. 2011. CD161highCD8+T cells bear pathogenetic potential in multiple sclerosis. Brain 134:542-54
193. Willing A, Leach OA, Ufer F, Attfield KE, Steinbach K, et al. 2014. CD8+ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur. J. Immunol. 44:3119-28
194. Cho YN, Kee SJ, Kim TJ, Jin HM, Kim MJ, et al. 2014. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. J. Immunol. 193:3891-901
195. Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, et al. 2015. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J. Clin. Investig. 125:1752-62
196. Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, et al. 2014. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin. Exp. Immunol. 176:266-74
197. Hiejima E, Kawai T, Nakase H, Tsuruyama T, Morimoto T, et al. 2015. Reduced numbers and proapoptotic features of mucosal-associated invariant T cells as a characteristic finding in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 21:1529-40
198. McEwen-Smith RM, Salio M, Cerundolo V. 2015. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol. Res. 3:425-35
199. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. 2007. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med. 204:2641-53
200. CroweNY, SmythMJ, Godfrey DI. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-27
201. Swann J, Crowe NY, Hayakawa Y, Godfrey DI, Smyth MJ. 2004. Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol. Cell Biol. 82:323-31
202. Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, et al. 2009. Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Investig. 119:1524-36
203. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, et al. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167:3114-22
204. Robertson FC, Berzofsky JA, TerabeM. 2014. NKT cell networks in the regulation of tumor immunity. Front. Immunol. 5:543
205. Chang DH, Deng H, Matthews P, Krasovsky J, Ragupathi G, et al. 2008. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood 112:1308-16
206. de Lalla C, Rinaldi A, Montagna D, Azzimonti L, Bernardo ME, et al. 2011. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4-subset dynamics and correlates with remission state. J. Immunol. 186:4490-99
207. Rubio MT, Moreira-Teixeira L, Bachy E, Bouillie M, Milpied P, et al. 2012. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood 120:2144-54
208. Peterfalvi A, Gomori E, Magyarlaki T, Pal J, Banati M, et al. 2008. Invariant Vα7.2-Jα33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells. Int. Immunol. 20:1517-25
209. Terabe M, Berzofsky JA. 2012. Natural Killer T Cells: Balancing the Regulation of Tumor Immunity. New York: Springer
210. NiedaM,OkaiM,Tazbirkova A, LinH, Yamaura A, et al. 2004. Therapeutic activation ofVα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383-89
211. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, et al. 2009. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol. 182:2492-501
212. Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, et al. 2013. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121:423-30
213. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, et al. 2011. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 138:255-65
214. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, et al. 2005. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11:1910-17
215. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, et al. 2008. Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57:337-45
216. Bai L,Deng S, Reboulet R, Mathew R, Teyton L, et al. 2013. Natural killerT(NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. PNAS 110:16097-102
217. Cavallari M, Stallforth P, Kalinichenko A, Rathwell DC, Gronewold TM, et al. 2014. A semisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice. Nat. Chem. Biol. 10:950-56
218. Anderson RJ, Tang CW, Daniels NJ, Compton BJ, Hayman CM, et al. 2014. A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy. Nat. Chem. Biol. 10:943-49
219. Agea E, Russano A, Bistoni O, Mannucci R, Nicoletti I, et al. 2005. Human CD1-restricted T cell recognition of lipids from pollens. J. Exp. Med. 202:295-308
220. LeeWY, Moriarty TJ,Wong CH, Zhou H, Strieter RM, et al. 2010. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat. Immunol. 11:295-302
221. Kawakami K, Kinjo Y, Uezu K, Yara S, Miyagi K, et al. 2001. Monocyte chemoattractant protein-1-dependent increase of Vα14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J. Immunol. 167:6525-32